摘要
目的对比在不同的结果判定标准下胃食管结合部癌中人表皮生长因子受体2（HER2）的表达情况及其与临床病理学因素的关系。方法回顾性分析2009年1—12月间北京大学肿瘤医院外科收治的127例胃食管结合部癌患者的临床资料．并对手术标本进行免疫组织化学（免疫组化）染色。结果采用新的和传统的HER2免疫组化判定标准、HER2阳性表达率均为15．0％（19／127），强阳性率则分别为10．2％（13／127）和6．3％（8／127）（P=0．26）。单因素分析显示．HER2表达与胃食管结合部癌肿瘤分化程度和Lauren分型有关：多因素分析则显示，肿瘤分化程度和TNM分期是影响HER2在胃食管结合部癌表达的独立因素（均P〈0．05）。结论新旧两种免疫组化判定标准下HER2的阳性率并无差异；HER2在胃食管结合部癌中的表达与临床病理特征关系密切。
Objective To compare the expression of human epidermal growth factor receptor 2 （HER2） under different scoring systems in gastroesophageal cancer and its relationship with clinicopathological features. Methods Clinicopathological data were retrospectively reviewed of 127 patients with gastroesophageal cancer between January and December 2009 in the Department of Surgery at the Cancer Hospital of Peking University. Tumor specimens were collected. The expression of HER2 protein was detected by immunohistochemistry. Results HER2 positive rate（-H-/＋H-） in gastroesophageal cancer was 15.0%（19/127）with both new and traditional immunohistochemical scoring systems, while HER2 strong positive rate（-s＋） was 10.2%（13/127） and 6.3%（8/127）, respectively（P=0.26）. Univariate analysis showed that the expression rate of HER2 protein was associated with differentiation and Lauren classification of the tumor. Multivariable analysis showed that TNM staging and tumor differentiation were independently associated with the expression of HER2 protein （both P〈0.05）.Conclusions There is no change in HER2 positive rate in gastroesophageal cancer between the new and traditional immunohistochemical scoring systems. Expression of HER2 is associated with clinicopathological features in the gastroesophageal cancer.
出处
《中华胃肠外科杂志》
CAS
北大核心
2011年第5期356-359,共4页
Chinese Journal of Gastrointestinal Surgery
基金
国家自然科学基金（81071983）
首都医学发展科研基金（2007-2051）
北京市科技新星计划项目资助项目（2007-B057）
关键词
胃食管结合部癌
人表皮生长因子受体2
免疫组织化学
Gastroesophageal neoplasms
Human epidermal growth factor receptor 2
Immunohistochemistry
